-
Mashup Score: 3ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate Cancer - 2 year(s) ago
Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Tips for optimizing an advanced prostate cancer clinic - 2 year(s) ago
In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Tips for optimizing an advanced prostate cancer clinic https://t.co/FUGKFA3PvW #LUGPA2022 #urology #urologist #prostatecancer @HafronJason
-
-
Mashup Score: 0
JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients
Source: www.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet-
Did you know @JELMYTO patients can present with diverse characteristics and histories? The JELMYTO team is here at #LUGPA2022 to guide you through an interactive ID experience. https://t.co/6s5VCidUn6 #Urology #Sponsored https://t.co/1Ksme2rB99
-
-
Mashup Score: 1Role of PSMA-PET Expands in the Treatment of Prostate Cancer - 2 year(s) ago
David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Role of PSMA-PET Expands in the Treatment of Prostate Cancer @UrologyUS #pcsm #LUGPA2022 #LUGPA22 https://t.co/rVD3zEBHoY
-
-
Mashup Score: 0
Webster also shares his advice for young urologists entering community practice.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. J. Christopher Webster on the biggest challenge facing his urology practice https://t.co/eEmuwleaQv #LUGPA2022 #urology #urologist @UnitedUrology
-
-
Mashup Score: 0
“We’re seeing that it’s beneficial to the patient—it’s easier, they don’t require a general anesthetic, and we don’t have to bring him to the hospital,” says Dr. Hafron.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Hafron explains the benefits of Jelmyto in UTUC since its approval https://t.co/ohzhbA1FXl #LUGPA2022 #urology #urologist @HafronJason
-
-
Mashup Score: 0
Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Shore Unpacks Treatment Advances for Patients With Urologic Cancers @nealshore @BradFiglerMD @CAmarasekera @dkbowen_md @CaPsurvivorship @CURCMB @GenesisCareUS @UrologyUS #pcsm #LUGPA2022 #LUGPA22 https://t.co/i8u011VMTB
-
-
Mashup Score: 0Home | JELMYTO® (mitomycin) for pyelocalyceal solution - 2 year(s) ago
JELMYTO is the first and only FDA-approved treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients
Source: www.jelmyto.comCategories: General Medicine News, Latest HeadlinesTweet-
Expanding your ways of thinking at #LUGPA2022? Visit the @JELMYTO booth to talk technology, treatment approaches, and patient characteristics. Learn about JELMYTO: https://t.co/ZEYS3Sl2RL #Urology #Sponsored https://t.co/bdkYuIyMQS
-
-
Mashup Score: 0Dr. Antonarakis describes optimal populations for genetic testing in prostate cancer - 2 year(s) ago
“We have to separate the need for germline testing and somatic testing,” explains Emmanuel S. Antonarakis, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Antonarakis describes optimal populations for genetic testing in prostate cancer https://t.co/yNvbGYALIp #LUGPA2022 #urology #prostatecancer @EAntonarakis @UMNCancer
-
-
Mashup Score: 0
In an interview during the 2022 LUGPA Annual Meeting, Ashley Ross, MD, PhD, discussed angoing advances and unmet needs in prostate cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Dr. Ashley Ross on the biggest recent advances in prostate cancer https://t.co/kx4mzsHuJL #LUGPA2022 #urology #urologist #prostatecancer @NM_Urology
-
ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate Cancer @CaPsurvivorship @DanaFarber @harvardmed @UrologyUS #pcsm #LUGPA2022 #LUGPA22 https://t.co/p7OXF5ohIW